Vgenomics India, a startup in biotechnology and healthcare, successfully concludes its seed funding round, led by Mumbai Angels and O2 Angel Network. The investment round also features the active participation of notable Angel investors, including Rohit Chanana and Sabine Kapasi. The strategic investment by Mumbai Angels, now part of 360 ONE, marks a significant advancement in the field, expanding its portfolio. The seed funding will play a crucial role in supporting Vgenomics' mission to develop diagnostic solutions and expand its business, particularly targeting neonatologists, gynecologists, pediatricians, and clinical geneticists.

This funding round not only affirms the effectiveness of their innovative strategy but also paves the way for the accelerated development and deployment of solutions to meet the needs of the staggering 175 million children worldwide affected by rare diseases. Vgenomics employs next-generation sequencing technologies, coupled with genomics and artificial intelligence, to develop diagnostics and therapeutics for rare childhood diseases. These conditions, present at birth and often caused by DNA alterations, pose a significant global healthcare challenge. Through the utilization of cutting-edge technologies, Vgenomics aims to introduce novel solutions to the market, making a substantial impact on the lives of millions of children.

Nandini Mansinghka, CEO of Mumbai Angels, commended Vgenomics' groundbreaking approach, stating, "Vgenomics' innovative strategy of harnessing next-generation, AI-powered sequencing technologies to address rare diseases is admirable. We believe this investment not only validates their innovative approach but also propels the journey towards making a meaningful impact on the lives of millions of children affected by rare diseases worldwide".